Metformin, a prescribed drug for type 2 diabetes, has been reported to have anti-cancer effects; however, the underlying mechanism is poorly understood. Here we show that this mechanism may be immune-mediated. Metformin enabled normal but not T-cell-deficient SCID mice to reject solid tumors. In addition, it increased the number of CD8 + tumor-infiltrating lymphocytes (TILs) and protected them from apoptosis and exhaustion characterized by decreased production of IL-2, TNFα, and IFNγ. CD8
Metformin, a prescribed drug for type 2 diabetes, has been reported to have anti-cancer effects; however, the underlying mechanism is poorly understood. Here we show that this mechanism may be immune-mediated. Metformin enabled normal but not T-cell-deficient SCID mice to reject solid tumors. In addition, it increased the number of CD8 + tumor-infiltrating lymphocytes (TILs) and protected them from apoptosis and exhaustion characterized by decreased production of IL-2, TNFα, and IFNγ. CD8
+ TILs capable of producing multiple cytokines were mainly PD-1 − Tim-3 + , an effector memory subset responsible for tumor rejection. Combined use of metformin and cancer vaccine improved CD8
+ TIL multifunctionality. The adoptive transfer of antigen-specific CD8 + T cells treated with metformin concentrations as low as 10 μM showed efficient migration into tumors while maintaining multifunctionality in a manner sensitive to the AMP-activated protein kinase (AMPK) inhibitor compound C. Therefore, a direct effect of metformin on CD8 + T cells is critical for protection against the inevitable functional exhaustion in the tumor microenvironment.
immune exhaustion | CD8T cells | antitumor immunity | tumor microenvironment | multifunctionality I n chronic infectious diseases and cancer, CD8
+ T cells specific for viral and/or tumor antigens undergo repeated TCR stimulation because of persistent pathogens or cancer cells and gradually lose their ability to secrete IL-2, TNFα, and IFNγ, eventually undergoing apoptotic elimination in a process known as immune exhaustion (1) . This worsening immune function is accompanied by phenotypic changes in CD8 + T cells, including the expression of exhaustion markers such as PD-1 and Tim-3 (2) . Antitumor immunity is enhanced in mice deficient in PD-1 or its ligands PDL-1 and PDL-2 (2-4). Galectin 9, a Tim-3 ligand, is secreted by many tumor cells as well as by FoxP3-expressing regulatory T-cell (Treg) and inhibits Tim-3-expressing Th1 cells (5) . An anti-Tim-3 antibody that blocks the galectin 9-Tim-3 pathway was found to accelerate antitumor immunity (6) . Furthermore, the administration of blocking antibodies against both PD-1 and Tim-3 induced a more profound tumor rejection in comparison with that achieved with either antibody alone (7) . The management of functional T-cell exhaustion within tumor tissues is currently an extensive focus in tumor immunotherapy (8, 9) , together with efforts to neutralize immune-inhibitory Treg and myeloid-derived suppressor cell (MDSC).
Metformin (dimethylbiguanide) has been widely prescribed for type 2 diabetes. Its unique pharmacological features include its antihyperglycemic efficacy, which counters insulin resistance (10, 11) . Early metformin use increases the survival of patients with obesity-involved type 2 diabetes and/or cardiovascular disease (12) . In addition, recent reports have described the unexpected anticancer effects of metformin in patients with type 2 diabetes (13) . Insulin-based diabetes treatment is associated with an increased cancer risk (14) (15) (16) (17) , whereas metformin use has been shown to decrease the frequency of specific cancers (18) (19) (20) (21) . Two independent metaanalyses of epidemiological studies concluded that compared with other treatments, metformin is associated with a 30-40% reduction in the incidence of cancer among patients with type 2 diabetes, indicating the need to investigate the anticancer mechanisms of metformin and conduct long-term randomized controlled trials (RCTs) (22, 23) .
In the HER-2/neu transgenic mouse breast cancer model, metformin treatment decreased the tumor burden and was associated with an increased life span (24) . Combined use of metformin with chemotherapeutic agents such as cisplatin has also yielded clinical benefits (25, 26) . Regarding the anticancer mechanism, metformin appears to preferentially kill cancer-initiating/stem cells from glioblastoma (27) , breast (28) and ovarian cancers (29) via AMPactivated protein kinase (AMPK) activation.
In contrast to the inhibitory action of metformin on tumor cells, here we demonstrate the direct effects of metformin on CD8 + T cells, which eventually results in tumor growth inhibition. Metformin protects CD8
+ tumor-infiltrating lymphocytes (TILs) from apoptosis, and the multifunctionality of exhausted PD-1
+ TILs is restored via a shift from a central memory (TCM) to an effector memory T-cell (TEM) phenotype. This metformin-induced antitumor mechanism is therefore linked to marked changes in the characteristics of CD8 + TILs within the tumor microenvironment.
Results
Metformin-Induced Tumor Rejection Depends on CD8 + T Cells. As metformin has been reported to decrease the rate of cancer incidence in type 2 diabetic patients, we at first examined whether
Significance
The multifunctional ability of CTLs is downregulated by interaction between immune-checkpoint molecules expressed on CTLs and their ligands expressed on cancer cells, referred to as immune exhaustion. The antibody-mediated, immune-checkpoint blockade turned out to a promising method for immunotherapy against advanced melanoma. Metformin, a drug prescribed for patients with type 2 diabetes, has been recognized to have anti-cancer effect. We found that CD8 + tumor infiltrating lymphocytes (TILs) is a target of metformin. CD8 the drug could protect mice from methylchoranthrene-induced skin carcinogenesis. BALB/c mice were injected with 200 μg of methylchoranthrene on the right back and given 5 mg/mL metformin dissolved in the drinking water throughout the experiment. Significant inhibition of tumor development was observed in metformin-treated nondiabetic mice (Fig. S1A) . We next attempted to determine whether metformin would be effective against an established solid tumor. Mice were intradermally injected with X-ray-induced RLmale1 leukemia cells and were provided oral metformin beginning on day 7. The tumors were gradually and completely rejected with no reappearance after metformin withdrawal. A rechallenge with more than twice the original number of the same tumor cells did not yield mass formation (Fig. 1A, Left) , suggesting the generation of an immunologic memory response. Moreover, the antitumor effect was completely abrogated in SCID mice (Fig. 1A, Right) , clearly demonstrating the necessity of T and/or B cells. Cytotoxic T lymphocytes (CTLs) specific for the tumor antigen peptide pRL1a (30) were generated in mice that rejected the tumor (Fig.  S1B) . Growth inhibition was observed with a metformin dose as low as 0.2 mg/mL (Fig. S1C) . Of note, a previous report identified the achievement of plasma metformin concentrations of 0.45 and 1.7 μg/mL using 1 and 5 mg/mL of metformin, respectively, in drinking water (31); these plasma concentrations are similar to those in patients with diabetes treated using metformin (0.5-2 μg/mL). Administration of metformin beginning on day 0, the time point of tumor inoculation, resulted in more effective rejection than on day 7. Beginning treatment on day 10 and 13 was also effective, although the effect was less than on day 0 (Fig.  S1D) . Finally, as expected, CD8
+ but not CD4 + T cells were proven to be responsible for the antitumor effect, because their depletion by mAb completely abrogated the response (Fig. 1B) . Complete rejection by metformin was also observed with Renca (renal cell carcinoma), although partial but significant growth inhibition was observed with other tumors, 3LL (non small cell lung carcinoma), Colon 26 (intestinal carcinoma), and 4T1 (breast cancer) (Fig. S1 E-H).
Metformin Prevents Apoptosis of CD8
+ TILs, Irrespective of Expression of PD-1 and Tim-3. Injection of a vaccine consisting of antigen (Ag) and adjuvant primes and generates specific T-cell immunity, mainly in draining lymph nodes near the injection site. However, we did not inject tumor antigens with any kind of adjuvant in Fig. 1 . Therefore, it is possible that a unique process occurs at the tumor site and leads to antitumor immunity. Based on this notion, we focused on TILs throughout the experiment to clarify the associated mechanism. We found that total numbers of TILs dramatically increased when metformin administration was started on day 7, and that both CD8
+ and CD4 + T cells were involved in the increment (Fig. 1 C-E) . In particular, the number of CD8
+ TILs increased nearly fourfold. We considered the possibility that metformin may suppress expression of the immune exhaustion markers PD-1 and Tim-3 on CD8 + TILs, thus avoiding immune exhaustion. Therefore, we investigated the expression of these markers on CD8
+ TILs derived from individual tumor-bearing mice (Fig. S1B) . The number of PD-1
CD8
+ TILs decreased from day 7-10, irrespective of metformin use (Fig. S2B) TILs stained with Annexin V were plotted (F). All data were with SD (n = 14 on days 7 and 10, n = 5 on day 13). The horizontal bars indicate median values, and P values obtained by two-tailed Student's t test are shown as *P < 0.05, **P < 0.01 n = 5-14 in each group. Each symbol represents an individual mouse. The results depicted are a summary of three independent experiments. Annexin V (Fig. 1F and Fig. S3A ), and that metformin suppressed apoptosis induction in all subsets, including PD-1
−

Tim-3
+
CD8
+ TILs (Fig. S3 B-E). Of note, the physiologically essential apoptotic process of CD4 +
+ thymocytes, which depends on a mitochondrial pathway (32), was not down-regulated by metformin (Fig. S4) , suggesting that an apoptotic mechanism unique to the tumor microenvironment is metformin-sensitive.
We next examined the metformin effects in another tumor system. MO5 is a subclone of B16 melanoma cells expressing ovalbumin (OVA) (33) . Metformin administration induced significant antitumor activity ( Fig. 2A) . OVA-and TRP2-specific CD8 + TILs were identified by specific tetramers. Both TIL populations in untreated mice decreased gradually from day 7-13; in contrast, metformin administration maintained or increased these populations (Fig. 2B) . CD8
+ TILs again underwent apoptosis, which was suppressed by metformin administration (Fig. S5 A and B) . The Annexin V-positive populations among OVA tetramer-positive and -negative (includes TRP-2-positive population) CD8 + TILs were near 80% at day 10; however, metformin suppressed this rate to <20-40% (Fig. S5 C and D) . These results are consistent with those observed in the RLmale1 model. Next, to examine the functional state of antigen-specific TILs, magnet-purified CD8 + TILs isolated from tumor tissues were incubated with DC-like DC2.4 cells that had been pulsed with an epitope peptide (OVA 257-264 ); TILs were later examined for their cytokine production capacity. Only IFNγ-producing cells or very small populations producing both IFNγ and TNFα or IL-2 could be identified in untreated mice, whereas a marked increase in the population producing both IFNγ and TNFα was observed with metformin ( Fig. 2C) . (34, 35) . TCM were shown to mediate viral-specific recall responses. Based on this model, we investigated TCM and TEM CD8 + TILs. Without metformin, the staining of CD8
+
TILs from an RLmale1 tumor using antibodies against CD62L and CD44 revealed that proportions of TCM and TEM were nearly equal on day 7 and 10 but shifted to TCM dominance on day 13. In contrast, metformin maintained TEM dominance from day 10 to day 13 ( Fig. 3A) . Further dissection of the TIL compartment based on CD62L and KLRG1 expression revealed that short-lived effector T cells (TE; CD62L low KLRG1 high ) were visible on day 7 but gradually decreased by day 13. In contrast, metformin yielded increases in both TEM and TE populations on day 13 ( Fig. 3B) , coinciding with tumor regression (Fig. 1A) . In the MO5 model, metformin again caused TEM dominant over TCM ( Fig. 3 C and D) . At this stage, we concluded that TEM and/or TE are more responsible than TCM for tumor rejection.
Metformin Induced Multifunctional CD8
+ TEM Expressing the Exhaustion Marker Tim-3. We next investigated the capacity for triple cytokine (IL-2, TNFα, IFNγ) production or the multifunctionality of CD8 + TILs in the context of TCM/TEM classification. CD8 + TILs recovered from RLmale1 tumor masses were stimulated with PMA/ ionomycin for 6 h in vitro and monitored for cytokine production. Without metformin, the cytokine-producing cells on day 10 were mainly identified as TCM (Fig. 4A ). In contrast, with metformin, triple cytokine-producing cells appeared in correlation with the increased population of TEM ( low (effector memory; EM) and CD62L low , KLRG1 high (effector; E) in RLmale1 and MO5 are shown in B and D, respectively. *P < 0.05, **P < 0.01. multiple (triple and double) cytokines are most important for tumor rejection. We next classified CD8 + TILs on the basis of their expression of PD-1 and Tim-3, followed by intracellular cytokine staining. We found that CD8
+ TILs with triple cytokineproducing abilities belonged exclusively to the PD-1 − Tim-3 + subset, which was the supposedly exhausted population in the RLmale1 tumor model (Fig. S6) . We further confirmed this notion using adoptive transfer experiments. MO5-inoculated mice were adoptively transferred with OT-I CD8 + T cells. The transferred T cells had been previously shown to undergo vigorous division and were thus cross-primed in vivo via the adjuvant-free administration of a fusion protein comprising OVA and Mycobacterium heat shock protein 70 (OVA-mHSP70) as a vaccine (36, 37) . OVA-mHSP70 injection significantly enhanced the migration of the transferred CD45.1 +
OT-I CD8
+ T cells into the tumor tissues; however, the cytokine-producing abilities of these cells were poor (Fig. 5A) . In contrast, injection of the fusion protein together with oral metformin administration apparently improved the multifunctionality of the migrated T cells, which were classified as the Tim-3 + population (Fig. 5A ).
Metformin-Treated Antigen-Specific Naïve CD8 T Cells Migrate into Tumors and Exert Antitumor Immunity Following Adoptive Transfer.
It is unknown whether plasma metformin concentrations as low as 10 μM (1.6 μg/mL) would directly influence the fate of T cells. To address this important question, we incubated CD8 + T cells isolated from naïve OT-I mice with 10 μM metformin for 6 h in the presence or absence of different doses of the AMPK inhibitor compound C (38) as indicated (Fig. 5B) . After extensive washing, the cells were transferred into MO5-bearing mice. Two days later, splenic T cells and TILs were recovered and investigated for the presence and multifunctionality of donorderived CD8
+ T cells. Metformin-treated CD8 + TILs comprised up to 9.9% of all CD8
+ T cells and were identified as triple cytokine-producing cells (Fig. 5B) . However, compound C treatment abrogated the migration, although donor CD8 + T cells were present in the spleens of all groups (Fig. 5B) . Accordingly, tumor growth inhibition was apparent in the metformin-treated group, although this effect was blocked by compound C (Fig.  5C ). The weak but significant metformin-mediated increase in the phosphorylation of AMPK and its downstream target acetylCoA carboxylase (ACC) and the abrogation of this effect by compound C were observed by Western blot analysis (Fig. 5D) . The results led us to conclude that the direct action of metformin on CD8
+ T cells, at least partly, reduced their exhaustion within the tumor microenvironment in a manner sensitive to the AMPK inhibitor compound C.
AMPK Phosphorylation, Enhanced Bat3 Expression, and Caspase-3
Inhibition Mediated by Metformin. Finally, we examined the expression of CD8 + TIL molecules that may possibly be influenced by metformin administration. After CD8 + TIL purification on day 10, cell lysates were immediately prepared for candidate molecule detection via Western blot analysis and for caspase-3 activity measurement using a fluorescent substrate. The levels of phosphorylated AMPKα and β were increased; a twofold increase in Bat3 expression was also observed, whereas Bcl2 and Bax expression were unaltered (Fig. S7A) . As expected, caspase-3 activity was prominent without metformin but was completely abrogated in CD8 + TILs from metformin-treated mice (Fig.  S7B ), which offers a plausible explanation for apoptosis inhibition. To further examine the apoptotic cell populations, we evaluated the expression of active caspase-3 in TCM, TEM, and TE. Without metformin, TCM, TEM, and TE all expressed active caspase-3 whereas with metformin, primarily TCM expressed this activated enzyme (Fig. S7C) . These results may explain the dominance of TCM over TEM in the absence of metformin and the dominance of TEM and TE in the presence of metformin. pS6, a downstream target of mTOR, was positive in TCM, TEM, and TE without metformin but negative with metformin ( Fig. S7D) , indicating that metformin inhibits mTOR, possibly via AMPK activation.
Discussion
In this report, we showed that established solid tumors are regressed by oral administration of metformin, and that CD8 + T cells mediate this effect. The number of FoxP3 expressing CD4 + regulatory T cells (Treg) has been implicated as a critical component in suppressing tumor immunity (39) . However, their numbers were not decreased, rather, transiently increased by metformin administration in RLmale 1 tumor model (Fig. S8) . Upon tumor rejection, the treated mice became resistant to rechallenge with the same tumor, providing proof of memory T-cell generation. Because no protective effect was observed in SCID mice, the direct killing of tumor cells by metformin is negligible. apoptosis marker; however, the effect was abrogated by CD8 T-cell depletion (Fig. S9 ). Our used model systems comprised highly immunogenic tumors, and it is unclear whether metformin would have the same effect on less immunogenic tumors. Demonstration of a similar effect in an autochthonous tumor model would be required in the future. Nonetheless, metformin countered apoptotic induction and reduced cytokine production in CD8 + TILs and thus blocked immune exhaustion within the tumor tissues we tested. The adoptive transfer experiment shown in Fig. 5 further demonstrated that the direct effect of metformin on CD8 + T cells, even at a physiologically relevant low concentration, markedly altered the cells' multifunctionality following migration into the tumor. Experiments with a genetic approach will be required to fully demonstrate whether this effect is mediated via AMPK activation in CD8 + T cells, because compound C is not highly specific for AMPK.
Dissection of TILs from the point of view of memory T cells in the context of multifunctionality provides mechanistic insight into metformin-induced antitumor immunity. Memory T cells have been classified as TCM, migrating between lymphoid organs, and TEM, circulating principally in the blood, spleen and peripheral tissues (34, 35, 40) . In acute virus infection models, as the virus is cleared, the population of TCM progressively increase, whereas the total numbers of TEM rapidly decrease (41) . The naturally occurring proportional shift from TEM to TCM, however, was not associated with metformin-induced rejection in the tumor models. For example, in the absence of metformin in the RLmale1 model, the TCM population gradually increased to exceed the TEM population by day 13 (Fig. 3 A and B) ; however, this proportional shift to TCM was associated with progressive tumor growth rather than tumor regression. Metformin possibly affects the TCM/TEM ratio by regulating TEM apoptosis (Fig. S7C) . The consequent decreased TCM/TEM ratio was apparently associated with antitumor activity in both the RLmale1 and MO5 models.
Analysis of the cytokine-producing capacities of CD8 + TILs also revealed the importance of TEM over TCM. A significant proportion of the CD8 + TIL population was maintained by metformin and produced IL-2, TNFα, and IFNγ. These triple cytokineproducing CD8 + TILs were exclusively of the PD1 − Tim3 + phenotype (Fig. S6) , which is committed to a TEM rather than a TCM fate (Fig. 4) . Moreover, although therapeutic vaccination with OVA-mHSP70 stimulated the migration of adoptively transferred OT-I CD8 + T cells into tumor tissues, these TILs lost multifunctionality (Fig. 5A) . Possibly, the cells were exhausted from the tumor microenvironment. Coadministration of metformin, however, led to the activation of the migrated Tim-3 + OT-I CD8 + T cells and the production of multiple cytokines (Fig. 5A ). Therefore, combined use of metformin and cancer vaccines may improve the efficacy of the vaccine. These findings provide novel insights into anticancer immunity. It is possible that tumor persistence stimulates the development of CD8 + TILs into TCM cells, which will immediately become useless against tumor growth because of immune exhaustion, and that metformin counters this situation, leading to the conversion of TCM to activated-state TEM that are fully active against tumors, despite exhibiting the surface phenotype of an exhausted cell (e.g., Tim-3 expression).
A previous report found that metformin treatment following vaccination with attenuated Listeria monocytogenes expressing OVA (LmOVA) protected mice from challenge by tumor cells expressing OVA (42) . This effect was caused by metformin-induced expansion of memory T cells after vaccination. As the tumor challenge occurred after metformin withdrawal, it is a matter of a prophylactic vaccination effect, which is different from the effects on immune exhaustion states in the tumor microenvironment. mTOR inhibition is among the downstream consequences of AMPK signaling, which is activated by metformin. Therefore, rapamycin, an inhibitor of mTORC1, may share mechanistic effects with metformin. Rapamycin has been shown to promote the generation of memory T cells (42) (43) (44) particularly in viral infection models. A common feature in the results was the increased population of TCM over TEM consequent to rapamycin treatment (45) . In our tumor models, however, metformin treatment preferentially increased the TEM population. It remains possible that additional pharmacological effects are involved in response to metformin versus rapamycin treatment. Further experiments will be required to elucidate cellular and molecular mechanism underlying metformin-induced reversion of exhausted CD8 + TILs.
Materials and Methods
Mice. BALB/c and C57BL/6 (B6) mice were purchased from CLEA Japan and SLC. Breeding pairs of CB-17 SCID mice were provided by K. Kuribayashi, Mie University School of Medicine, Mie, Japan.
Tumor Cell Lines. BALB/c radiation leukemia RLmale1, B6 OVA-gene introduced B16 melanoma MO5, B6 nonsmall cell lung carcinoma 3LL, BALB/c intestinal carcinoma Colon 26, BALB/c renal cell carcinoma Renca, and BALB/c breast cancer cell 4T1 were used for the tumor assay. 3LL, Colon 26, Renca, and 4T1 were kindly provided by H. Yagita, Juntendo University School of Medicine, Tokyo, Japan.
Tumor Growth Assay. Mice were intradermally inoculated with 2 × 10 5 tumor cells (in 0.2 mL) on the right back with a 27-gauge needle. Before inoculation of tumor cells, the hair was cut with clippers. Mice were orally administrated metformin hydrochloride (Wako) (5 mg/mL) or as indicated dissolved the drinking water. The diameter of the tumors was measured with Vernier calipers twice at right angles to calculate the mean diameter. ) prepulsed with graded doses of peptide in a 96-well round-bottom culture plate for 24 h at 37°C and 5% CO 2 . The stimulated culture supernatants were collected, and the amount of secreted IFNγ was measured using ELISA.
Supporting Information
Isolation of TILs. BALB/c or C57BL/6 mice were intradermally inoculated with 2 × 10 5 RLmale1 or MO5 cells on the right dorsal side. The tumor tissues were dissected from the mice and minced into small pieces in RPMI medium 1640 (Life Technologies). TILs were harvested from the minced tumor tissues using the Medimachine system (AS ONE). Lymphocytes (TILs) could be distinguished from tumor cells as their size is less than a half of tumor cells under microscope. Then, we stained all cells including TILs and tumor cells with indicated fluorescence-labeled antibodies and subjected them onto Flow cytometric analysis.
Flow Cytometric Analysis. Cells were washed and incubated with mAbs for 30 min at 4°C in 5 mM EDTA and PBS containing 2% FCS (FACS staining buffer). The following mAbs were used: APC-Cy7-conjugated anti-mouse CD8α (BD Biosciences), PECy7-conjugated anti-mouse CD4 (eBioscience), PE-conjugated anti-mouse PD-1 (eBioscience), Alexa Fluor 647-conjugated antimouse Tim-3 (BioLegend), PE-conjugated anti-mouse CD62L (eBioscience), FITC-conjugated anti-mouse CD44 (eBioscience), and APC-conjugated anti-mouse KLRG1 (eBioscience) for cell surface marker staining as well as PE-Cy7-conjugated anti-mouse IL-2 (BD Biosciences), PerCP/Cy5.5-conjugated anti-mouse TNFα (BD Biosciences), and FITC-conjugated anti-mouse IFNγ (eBioscience) for intracellular cytokine staining. PE-labeled anticleaved caspase-3 (Asp175) and Alexa Fluor 647-conjugated antipS6 (S235/236) (Cell Signaling Technology) were used for the detection of early apoptosis and mTOR downstream signaling, respectively. Intracellular cytokine staining was performed with a Fixation/Permeabilization kit (BD Biosciences). Early apoptosis was detected using Annexin-V-FITC (Sigma-Aldrich). After treatment, the cells were washed, suspended in FACS staining buffer, and analyzed on a FACSCanto II flow cytometer (BD Biosciences). We determined a suitable gate for lymphocytes (TILs), compared with that of spleen cells. Tumor cells are always larger than TILs, as determined by FSC-A and SSC-A. The gated populations for lymphocytes (TILs) were identified as CD4 After the stimulation culture, the cells were harvested and labeled with APC-Cy7-conjugated anti-mouse CD8, PE-conjugated anti-mouse PD-1, and Alexa Fluor 647-conjugated anti-mouse Tim-3, followed by intracellular cytokine staining for IL-2, TNFα, and IFNγ and flow cytometric analysis on a FACSCanto II.
Tetramer Staining. TILs were harvested as described above and incubated with PE-conjugated H-2K b OVA (SIINFEKL) and H-2K b TRP2 180-188 tetramers (Medical and Biological Laboratories) for 30 min at 4°C, followed by incubation with APC-Cy7-conjugated anti-mouse CD8α (Alpha Biomedical; APC-Cy7 conjugation was performed in our laboratory) for 30 min at 4°C and analysis on a FACSCanto II.
Adoptive Cell Transfer Experiment. CD45.1/OT-I CD8 + T cells were isolated from the splenocytes of OT-I transgenic mice via magnetic separation and were adoptively transferred (2 × 10 6 ) on day 7 into B6 mice (CD45.2) that had been inoculated with 3 × 10 5 MO5 cells on the right dorsal side. Simultaneously, 10 μg of the OVA-mHSP70 fusion protein was i.v. injected and 5 mg/mL of metformin was orally administered per mouse. Three days later, each right inguinal lymph node and each tumor tissue was resected, processed into single-cell suspensions, and pooled. These cells were stimulated with 1.25 ng/mL of PMA and 50 nM ionomycin for 6 h at 37°C and 5% CO 2 in the presence of Golgi stop, followed by staining with APC-Cy7-conjugated anti-mouse CD8, PE-conjugated anti-mouse CD45.1 (BD Biosciences), and Alexa Fluor 647-conjugated anti-mouse Tim-3 and intracellular staining for IL-2, TNFα, and IFNγ. In another adoptive transfer experiment, the transferred OT-I CD8 + T cells were pretreated in vitro with metformin (10 μM) for 6 h with or without compound C (5 and 50 μM). Two days after transfer, the cells were recovered from the spleens and tumors and subjected to a multifunctionality evaluation.
Intracellular FoxP3 Staining. Intracellular FoxP3 staining was performed using an anti-mouse FoxP3-FITC (eBioscience) staining buffer set (eBioscience) according to the manufacturer's instructions.
Immunoblot Analysis. CD8 + T cells were purified from tumor tissues via a magnet-based purification system (Miltenyi Biotec), lysed, and subjected to immunoblot analysis. Lysates were prepared by suspending cells in lysis buffer (PBS, 1% Nonidet P-40, 1 mM PMSF). The lysates were cleared by centrifugation and subjected to electrophoresis on a SDS (SDS)-polyacrylamide gel. The proteins were then transferred to nitrocellulose membranes, blocked with 1-10% dry milk in TBS-T [TBS (10 mM Tris·HCl pH 7.5, 135 mM NaCl) + 0.05% Tween-20]. Antigen-antibody complexes were visualized by chemiluminescence (ECL). Anti-AMPKα (1:1,000 dilution), anti-pAMPKα (Thr172; 1:1,000), anti-AMPKβ (1:1,000), anti-pAMPKβ (Ser108; 1:1,000), and anti-p-ACC (S79; 1:500) antibodies were purchased from Cell Signaling Technology. Anti-Bat3 (1:1,000; Abcam), anti-Bag1 (1:1,000; Medical and Biological Laboratories), anti-Bcl2 (1:1,000; Gene Tex), and anti-Bax (1:1,000; Gene Tex) were also used for Western blot analysis. Immunoblot images were cut and rearranged to remove irrelevant information; however, all lanes were obtained from the same blot with the same levels of exposure and contrast.
Measurement of Caspase-3 Activation. Caspase-3 activity was measured in a colorimetric assay using tetrapeptide methyl cumaryl amide (MCA) substrates. CD8
+ T cells were purified from tumor tissues via a magnet-based purification system (Miltenyi Biotec), lysed, and subjected to an immunoblot analysis. Lysates were also prepared by suspending cells in lysis buffer (25 mM Tris·HCl pH 7.5, 250 mM sucrose, 1 mM PMSF, 1 mM DTT, 1% Nonidet P-40). The assays were performed in 96-well black plates by incubating 10 μL (1 × 10 5 ) of cell lysate with 89 μL of reaction buffer (25 mM Tris·HCl pH 7.5, 250 mM sucrose, 1 mM PMSF, 1 mM DTT) containing 1 μL of peptide substrate (10 mM). The assays incorporated Acetyl-Asp-Asn-Leu-Asp-MCA (Peptide Institute). Absorbance at OD360/450 was monitored at 37°C for 3 h using a Powerscan HT (DS Pharma Biomedical). For certain experiments, the cell lysate was diluted in the assay buffer as indicated.
Immunohistochemistry. Tumor tissues were removed and fixed by 4% PFA for 48 h. Consecutive 4 μm-thick sections were cut from each trimmed paraffin block. In brief, following deparaffinization, sections were rehydrated, treated with citrate buffer at 96°C for 30 min, and treated with 3% H 2 O 2 . The sections were incubated for overnight at 4°C with specific antibodies to Ki67 antigen (clone D3B5; Cell Signaling Technology(CST) Japan, Tokyo, Japan; 1:200) and cleaved caspase-3(Asp175) (clone 5A1E; CST Japan; 1:2,000). The slides were incubated with secondary antibodies (goat anti-rabbit HRP conjugated, CST Japan). The immunostaining was visualized with 3,3′-diaminobenzidine tetrahydrochloride (DAB) for 1-3 min and counterstained with hematoxylin for 5 min. Staining controls were prepared by replacing the primary antibody to buffer solution. All analyses were performed under a light microscope (4× or 40×).
Statistical Evaluation. Student's t test was used for statistical evaluations of normally distributed data. surface stained with antibodies against CD8, CD62L, CD44, and KLRG1 and intracellularly stained with antibodies against cleaved caspase-3 and phosphorylated S6, followed by flow cytometric analysis. ) of tumor. All data are expressed as the mean ± SD, n = 5-14 in each group. P values were obtained by twotailed Student's t test. *P < 0.05, **P < 0.01. 
